1.28
price up icon3.23%   0.04
after-market アフターアワーズ: 1.29 0.01 +0.78%
loading
前日終値:
$1.24
開ける:
$1.265
24時間の取引高:
518.94K
Relative Volume:
0.28
時価総額:
$146.69M
収益:
$13.45M
当期純損益:
$-178.23M
株価収益率:
-0.7758
EPS:
-1.65
ネットキャッシュフロー:
$-132.53M
1週間 パフォーマンス:
+13.27%
1か月 パフォーマンス:
+12.28%
6か月 パフォーマンス:
-4.48%
1年 パフォーマンス:
-77.02%
1日の値動き範囲:
Value
$1.265
$1.28
1週間の範囲:
Value
$1.12
$1.28
52週間の値動き範囲:
Value
$0.6611
$5.92

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
名前
Fate Therapeutics Inc
Name
セクター
Healthcare (1163)
Name
電話
858.875.1803
Name
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
職員
181
Name
Twitter
@fatethx
Name
次回の収益日
2025-05-02
Name
最新のSEC提出書
Name
FATE's Discussions on Twitter

FATE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
FATE
Fate Therapeutics Inc
1.28 142.14M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-11-18 アップグレード BofA Securities Underperform → Neutral
2024-06-17 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-24 ダウングレード H.C. Wainwright Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2023-01-06 ダウングレード Cowen Outperform → Market Perform
2023-01-06 ダウングレード Piper Sandler Overweight → Neutral
2023-01-06 ダウングレード Stifel Buy → Hold
2023-01-06 ダウングレード Truist Buy → Hold
2023-01-06 ダウングレード Wedbush Outperform → Neutral
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-12-22 ダウングレード Oppenheimer Outperform → Perform
2022-12-15 開始されました Goldman Sell
2022-11-04 再開されました Cantor Fitzgerald Overweight
2022-10-10 開始されました Canaccord Genuity Buy
2022-08-18 再開されました Wells Fargo Overweight
2022-07-28 開始されました Needham Hold
2022-07-11 アップグレード BMO Capital Markets Market Perform → Outperform
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-11 再開されました BMO Capital Markets Market Perform
2021-12-15 アップグレード Wedbush Neutral → Outperform
2021-12-07 開始されました Cowen Outperform
2021-11-09 アップグレード Citigroup Neutral → Buy
2021-08-26 開始されました Morgan Stanley Equal-Weight
2021-06-07 アップグレード H.C. Wainwright Neutral → Buy
2021-05-07 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Jefferies Buy
2021-02-26 開始されました BofA Securities Buy
2021-02-26 ダウングレード Wedbush Outperform → Neutral
2021-02-11 ダウングレード Citigroup Buy → Neutral
2021-01-27 再開されました H.C. Wainwright Neutral
2020-05-13 開始されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-09 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-12-30 繰り返されました Mizuho Buy
2019-12-09 アップグレード Wells Fargo Market Perform → Outperform
2019-11-12 開始されました SunTrust Buy
2019-11-06 ダウングレード Wells Fargo Outperform → Market Perform
2019-10-01 開始されました Stifel Buy
2019-08-09 開始されました BTIG Research Buy
2019-07-22 開始されました Cantor Fitzgerald Overweight
2019-07-12 開始されました Oppenheimer Outperform
2019-06-13 開始されました Mizuho Buy
2019-06-07 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Buy
2019-05-24 再開されました Citigroup Buy
2019-03-28 開始されました SVB Leerink Outperform
2019-01-03 ダウングレード Stephens Overweight → Equal-Weight
2018-11-05 開始されました Jefferies Buy
2018-08-01 開始されました Citigroup Buy
2018-03-06 ダウングレード H.C. Wainwright Buy → Neutral
すべてを表示

Fate Therapeutics Inc (FATE) 最新ニュース

pulisher
06:49 AM

What analysts say about Fate Therapeutics Inc. stockSkyrocketing investment returns - jammulinksnews.com

06:49 AM
pulisher
01:26 AM

Is Fate Therapeutics Inc. a good long term investmentExceptional gains - Autocar Professional

01:26 AM
pulisher
12:10 PM

Fate Therapeutics Inc. Stock Analysis and ForecastLightning-fast capital gains - jammulinksnews.com

12:10 PM
pulisher
Jul 21, 2025

What drives Fate Therapeutics Inc. stock priceUnstoppable trading performance - Autocar Professional

Jul 21, 2025
pulisher
Jul 18, 2025

why fate therapeutics inc. stock attracts strong analyst attentionFree Day Trading Recommendations - Newser

Jul 18, 2025
pulisher
Jul 16, 2025

what makes fate therapeutics inc. stock price move sharplyIntraday Trade Ideas - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of “Hold” from Brokerages - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

How Fate Therapeutics Inc. stock performs during market volatilityMarket Beating Strategy - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Fate Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Fate Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully - Yahoo Finance

Jul 14, 2025
pulisher
Jul 11, 2025

10 Best Get Rich Quick Stocks to Buy Now - Insider Monkey

Jul 11, 2025
pulisher
Jul 05, 2025

Research Analysts Offer Predictions for FATE Q2 Earnings - Defense World

Jul 05, 2025
pulisher
Jul 03, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 03, 2025
pulisher
Jul 03, 2025

Fate Therapeutics shares rise 3.57% after-hours after granting non-qualified stock options to a new employee. - AInvest

Jul 03, 2025
pulisher
Jul 02, 2025

H.C. Wainwright maintains Neutral rating on Fate Therapeutics stock at $5 - Investing.com

Jul 02, 2025
pulisher
Jun 30, 2025

Fate Therapeutics, Inc.(NasdaqGM: FATE) added to Russell Microcap Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 28, 2025

Fate Therapeutics (NASDAQ:FATE) Downgraded to “Sell” Rating by Wall Street Zen - Defense World

Jun 28, 2025
pulisher
Jun 15, 2025

Institutional owners may take dramatic actions as Fate Therapeutics, Inc.'s (NASDAQ:FATE) recent 20% drop adds to one-year losses - simplywall.st

Jun 15, 2025
pulisher
Jun 14, 2025

Fate Therapeutics’ SWOT analysis: promising data boosts stock outlook - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

TC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical Review - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

Fate Therapeutics (NASDAQ:FATE) Given “Hold” Rating at Needham & Company LLC - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Needham maintains hold on Fate Therapeutics stock despite lupus data By Investing.com - Investing.com Canada

Jun 12, 2025
pulisher
Jun 12, 2025

Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? - Yahoo Finance

Jun 12, 2025
pulisher
Jun 11, 2025

Fate Therapeutics price target lowered to $2.20 by BofA on SLE data - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Fate Therapeutics (FATE) Shares Promising Data on FT819 for Lupus Treatment | FATE Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - The Manila Times

Jun 11, 2025
pulisher
Jun 11, 2025

Fate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025 - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Fate’s FT819 shows promising results in lupus patients - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Breakthrough: Fate's Off-the-Shelf CAR T-Cell Shows 100% Response Rate in Severe Lupus Patients - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Purchases 20,805 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Bank of America Corp DE Sells 550,066 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Comments on FATE FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance

Jun 10, 2025

Fate Therapeutics Inc (FATE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
大文字化:     |  ボリューム (24 時間):